Open an account

Braveheart Bio

BRVE · NASDAQ

$21.44−$0.04 (−0.19%)TodayMarket closed ·
Prev close $21.48

About BRVE

Braveheart Bio, Inc. is a US-based company operating in industry. The company is headquartered in San Francisco, California and currently employs 30 full-time employees. The company went IPO on 2026-08-06. Braveheart Bio, Inc. is a clinical stage biopharmaceutical company. The firm is focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. Its lead product candidate, BHB 1893, is an oral small-molecule cardiac myosin inhibitor (CMI), that it is developing for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM). Its pipeline is focused on advancing BHB-1893 across multiple cardiovascular indications with significant unmet need. HCM is a chronic, progressive disease characterized by abnormal thickening and impaired relaxation of the heart.

Employees
30
Headquarters
San Francisco, California
Listed
Aug 6, 2026
Sector
N/A
Industry
N/A
Website
braveheart.bio

BRVE key statistics

Market cap
1.93B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
431.88K
Volume
119.56K
Open price
$21.45
High today
$21.53
Low today
$20.58
52 Week high
$32.00
52 Week low
$17.86

Braveheart Bio (BRVE) at a glance

Braveheart Bio (BRVE) last traded at $21.44, with a market cap of 1.93B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $20.58 and $21.53. The current price is 4.2% above the day's low and 0.4% below its high.

Volume so far is 119.56K shares, below the average of 431.88K shares a day.

Over the past year Braveheart Bio has ranged from $17.86 to $32.00, and now sits 25% of the way up that range.

The average analyst price target is $46.15, 115.3% above the current price, from 5 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 5 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 6 analystsAvg $46.15
Low
$40.40
Now
$21.44
High
$50.40

BRVE news

  • Press releaseGlobe Newswire

    Braveheart Bio to Participate in Stifel Cardiometabolic Forum

  • Press releaseGlobe Newswire

    Braveheart Bio to Participate in Cantor Global Healthcare Conference

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.